Brief Summary:
The purpose of this study is to learn if V940 which is an individualized neoantigen
therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab
(MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma.
Researchers want to know if V940 with pembrolizumab is better than receiving
pembrolizumab alone at preventing the cancer from returning.
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has surgically resected and histologically/pathologically confirmed diagnosis of
Stage IIB or IIC, III, or IV cutaneous melanoma
- Has not received any prior systemic therapy for their melanoma beyond surgical
resection
- No more than 13 weeks have passed between final surgical resection that rendered the
participant disease-free and the first dose of pembrolizumab
- Is disease free at the time of providing documented consent for the study
- Human immunodeficiency virus (HIV)-infected participants must have well controlled
HIV on anti-retroviral therapy (ART)
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has ocular or mucosal melanoma
- Has cancer that has spread to other parts of the body and cannot be removed with
surgery
- Has heart failure within the past 6 months
- Has received prior cancer therapy or another cancer vaccine
- Has another known cancer that that has spread to other parts of the body or has
required treatment within the past 3 years
- Has severe reaction to study medications or any of their substance used to prepare a
drug
- Have not recovered from major surgery or have ongoing surgical complications
Primary outcome:
1. Recurrence-Free Survival (RFS) (Time Frame - Up to approximately 74 months):
RFS is defined as the length of time from when the participant starts the study until
either the cancer comes back, or the cancer spreads as assessed by the investigator, or
death due to any cause.
Secondary outcome:
1. Distant Metastasis-Free Survival (DMFS) (Time Frame - Up to approximately 85 months):
DMFS is the length of time from when the participant starts the study until either the
cancer spreads from where it started to other parts of the body as assessed by the
investigator, or death due to any cause.
2. Overall-Survival (OS) (Time Frame - Up to approximately 85 months):
OS is the length of time that people are alive after joining the study.
3. Number of Participants Who Experience an Adverse Event (AE) (Time Frame - Up to approximately 68 weeks):
An AE is a health problem that happens or worsens during a study. Number of participants
who experience an AE will be reported.
4. Number of Participants Who Discontinue Study Treatment Due to an AE (Time Frame - Up to approximately 56 weeks):
An AE is a health problem that happens or worsens during a study. Number of participants
who discontinue study treatment will be reported.
5. Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score (Time Frame - Baseline and up to approximately 85 months):
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of
cancer patients. Participant responses to the questions "How would you rate your overall
health during the past week?" and "How would you rate your overall quality of life during
the past week?" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using
linear transformation, raw scores will be standardized, so that scores range from 0 to
100. Higher scores indicate a better overall health status. Per protocol, the change from
baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.
6. Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 (Time Frame - Baseline and up to approximately 85 months):
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of
cancer patients. Participant responses to 5 questions about their physical functioning
will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear
transformation, raw scores will be standardized, so that scores range from 0 to 100.
Higher scores indicate a better level of physical functioning. The change from baseline
in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.
7. Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30 (Time Frame - Baseline and up to approximately 85 months):
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of
cancer patients. Participant responses to the questions "Were you limited in doing either
your work or other daily activities during the past week?" and " Were you limited in
pursuing your hobbies or other leisure time activities during the past week?" will be
scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a more
impaired level of role functioning. Change from baseline in the role functioning (EORTC
QLQ-C30 Items 6-7) combined score will be presented.
- Experimental: V940 + Pembrolizumab
Participants receive up to 9 doses of V940 via an intramuscular (IM) injection (every 3
weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6
weeks) until disease recurrence or unacceptable toxicity, or for a total treatment
duration of up to approximately 56 weeks, whichever is sooner. - Active Comparator: Placebo + Pembrolizumab
Participants receive up to 9 doses of dose matched placebo to V940 via an IM injection
(every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6
weeks) until disease recurrence or unacceptable toxicity, or for a total treatment
duration of up to approximately 56 weeks, whichever is sooner.
- V940 (mRNA-4157 / Individualized neoantigen therapy / ):
IM injection - Pembrolizumab (MK-3475 / Keytruda® / ):
IV infusion - Placebo (Normal saline / Dextrose / ):
IM injection
Quelle: ClinicalTrials.gov
